CIBC upgraded shares of Aphria (NYSE:APHA) from an underperform rating to a neutral rating in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. The brokerage currently has $7.00 target price on the stock.
Other research analysts have also recently issued research reports about the stock. ValuEngine cut shares of Aphria from a buy rating to a hold rating in a research report on Thursday, December 5th. Cantor Fitzgerald started coverage on shares of Aphria in a report on Tuesday, November 5th. They issued an overweight rating and a $10.40 price target for the company. Zacks Investment Research lowered shares of Aphria from a strong-buy rating to a hold rating in a report on Monday, January 6th. Bank of America began coverage on shares of Aphria in a research report on Monday, January 13th. They issued a neutral rating on the stock. Finally, Jefferies Financial Group set a $8.30 price target on shares of Aphria and gave the stock a buy rating in a research report on Tuesday, October 15th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Aphria presently has a consensus rating of Buy and an average target price of $12.09.
APHA stock opened at $5.27 on Tuesday. Aphria has a twelve month low of $3.76 and a twelve month high of $10.95. The company has a market cap of $1.29 billion, a PE ratio of -47.91, a price-to-earnings-growth ratio of 5.22 and a beta of 2.78. The business’s 50-day simple moving average is $4.97 and its 200 day simple moving average is $5.60.
Aphria (NYSE:APHA) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. The business had revenue of $126.10 million for the quarter, compared to the consensus estimate of $131.15 million. The business’s revenue for the quarter was up 848.1% compared to the same quarter last year. Research analysts predict that Aphria will post 0.03 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the company. LPL Financial LLC grew its holdings in Aphria by 57.3% in the second quarter. LPL Financial LLC now owns 61,291 shares of the company’s stock worth $430,000 after purchasing an additional 22,316 shares during the period. Renaissance Technologies LLC bought a new position in shares of Aphria during the second quarter valued at about $1,700,000. Toronto Dominion Bank lifted its position in shares of Aphria by 17.4% during the second quarter. Toronto Dominion Bank now owns 142,835 shares of the company’s stock valued at $1,005,000 after purchasing an additional 21,212 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Aphria by 76.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,248 shares of the company’s stock worth $44,000 after acquiring an additional 2,698 shares during the period. Finally, Private Advisor Group LLC raised its position in Aphria by 44.4% in the second quarter. Private Advisor Group LLC now owns 25,707 shares of the company’s stock worth $180,000 after acquiring an additional 7,906 shares during the period. Institutional investors own 9.60% of the company’s stock.
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
See Also: Monthly Dividend Stocks
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.